To the full analysis
Buyback calculator for Xeris Biopharma Holdings
Xeris Biopharma Holdings stock: key metrics
XERSXeris Biopharma Holdings had an operating margin of 8.5% and a return on invested capital (ROIC) of 15% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | 99.3% | −1,230.8% | −1,228.7% |
| 2017 | 99.7% | −1,711.4% | −1,706.6% |
| 2018 | 98.3% | −2,407.5% | −2,437.3% |
| 2019 | 41.1% | −4,496.0% | −4,613.5% |
| 2020 | 54.4% | −408.8% | −446.0% |
| 2021 | 73.1% | −232.2% | −247.5% |
| 2022 | 79.5% | −74.3% | −85.9% |
| 2023 | 82.5% | −26.8% | −38.0% |
| 2024 | 81.9% | −16.6% | −27.0% |
| 2025 | 81.7% | 8.5% | 0.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | 41.4% | −33.7% | −39.4% |
| 2017 | 45.9% | −59.1% | −59.0% |
| 2018 | −79.7% | −62.5% | −50.1% |
| 2019 | −100.0% | no data | −100.0% |
| 2020 | −100.0% | −62.1% | −57.3% |
| 2021 | −100.0% | −51.1% | −40.3% |
| 2022 | −100.0% | −64.0% | −27.5% |
| 2023 | 200.0% | −25.6% | −19.3% |
| 2024 | 185.2% | −16.6% | −17.0% |
| 2025 | 4.0% | 15.0% | 0.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.